Related Experiment Video
Updated: Jan 16, 2026

Generation of a RIP1 Knockout U937 Cell Line Using the CRISPR-Cas9 System
Published on: April 11, 2025
PPP1R3G Deletion Blocks RIPK1-Mediated Apoptosis and Necroptosis in Doxorubicin-Induced Cardiotoxicity
Abstract:
Cardiotoxicity is a major limitation of cancer chemotherapy, exemplified by doxorubicin (DOX), yet its underlying mechanisms remain incompletely defined. Here, we identify Protein Phosphatase 1 Regulatory Subunit 3G (PPP1R3G) as a critical amplifier of DOX-induced cardiotoxicity. We show that DOX activates both apoptosis and necroptosis in vitro. Mechanistically, DOX first induces p38-dependent inhibitory phosphorylation of receptor-interacting protein kinase 1 (RIPK1), providing a transient brake on cell death. PPP1R3G facilitates the removal of inhibitory phosphorylation, thereby permitting RIPK1 activation, oligomerization, and downstream apoptotic signaling. Activated RIPK1 further promotes mitochondrial DNA (mtDNA) release, which induces IFN-β-mediated ZBP1 expression and establishes a positive feedback loop that amplifies late-stage necroptosis. Genetic ablation of Ppp1r3g suppresses both apoptosis and necroptosis in cardiomyocytes, attenuates inflammatory cytokine production, and protects mice from DOX-induced cardiac injury and mortality. These findings delineate a PPP1R3G-RIPK1 axis that converts an early protective phosphorylation checkpoint into sustained death signaling and identify PPP1R3G as a potential therapeutic target for cardioprotection.
Insights
Doxorubicin (DOX) chemotherapy causes heart damage by activating cell death pathways. Protein Phosphatase 1 Regulatory Subunit 3G (PPP1R3G) amplifies this toxicity, making it a potential target for cardioprotection.
Area of Science:
- Molecular Biology
- Cardiology
- Oncology
Background:
- Cardiotoxicity is a significant challenge in cancer chemotherapy, particularly with drugs like doxorubicin (DOX).
- The precise molecular mechanisms driving DOX-induced cardiotoxicity are not fully understood.
Purpose of the Study:
- To identify key molecular players involved in doxorubicin-induced cardiotoxicity.
- To elucidate the role of Protein Phosphatase 1 Regulatory Subunit 3G (PPP1R3G) in mediating cardiac cell death.
Main Methods:
- Investigated DOX-induced apoptosis and necroptosis in cardiomyocytes in vitro.
- Utilized genetic ablation of Ppp1r3g in vivo to assess its protective effects.
- Examined the phosphorylation status of receptor-interacting protein kinase 1 (RIPK1) and downstream signaling pathways.
Main Results:
- DOX induces both apoptosis and necroptosis, initially transiently inhibited by p38-dependent RIPK1 phosphorylation.
- PPP1R3G removes inhibitory phosphorylation on RIPK1, promoting sustained cell death signaling.
- Activated RIPK1 triggers mitochondrial DNA release, IFN-β production, ZBP1 expression, and amplifies necroptosis.
- Ppp1r3g knockout mice showed reduced cardiac cell death, inflammation, and protection from DOX-induced injury.
Conclusions:
- The PPP1R3G-RIPK1 axis is a critical mediator of DOX cardiotoxicity, converting an early protective brake into sustained death signaling.
- Targeting PPP1R3G offers a potential therapeutic strategy for preventing chemotherapy-induced heart damage.
Related Concept Videos
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Regulation of the Unfolded Protein Response

